These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12410851)

  • 1. Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathy.
    Blanco S; Penin R; Casas I; López D; Romero R
    Kidney Int Suppl; 2002 Dec; (82):S27-31. PubMed ID: 12410851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis.
    Blanco S; Bonet J; López D; Casas I; Romero R
    Kidney Int Suppl; 2005 Jan; (93):S10-4. PubMed ID: 15613060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs.
    Navarro-Cid J; Maeso R; Rodrigo E; Muñoz-García R; Ruilope LM; Lahera V; Cachofeiro V
    Am J Hypertens; 1996 Nov; 9(11):1077-83. PubMed ID: 8931832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antihypertensive drugs on blood pressure and metabolic alterations in the fructose-induced hypertensive rat.
    Navarro-Cid J; Maeso R; Perez-Vizcaino F; Casal MC; Cachofeiro V; Ruilope LM; Tamargo J; Lahera V
    Am J Hypertens; 1996 Jul; 9(7):669-74. PubMed ID: 8806979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Combined Treatment with the (Pro)Renin Receptor Blocker HRP and Quinapril in Type 1 Diabetic Rats.
    Kökény G; Fang L; Révész C; Mózes MM; Vörös P; Szénási G; Rosivall L
    Kidney Blood Press Res; 2017; 42(1):109-122. PubMed ID: 28359068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril).
    Cabezas-Cerrato J; Garcia-Estevez DA; Araújo D; Iglesias M
    Metabolism; 1997 Feb; 46(2):173-8. PubMed ID: 9030825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
    Noda M; Matsuo T; Nagano-Tsuge H; Ohta M; Sekiguchi M; Shibouta Y; Naka T; Imura Y
    Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.
    Fredersdorf S; Weil J; Ulucan C; Birner C; Büttner R; Schubert T; Böger CA; Debl K; Muders F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):95-103. PubMed ID: 17333128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
    Hudkins KL; Wietecha TA; Steegh F; Alpers CE
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
    Kakimoto T; Okada K; Hirohashi Y; Relator R; Kawai M; Iguchi T; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
    J Endocrinol; 2014 Jul; 222(1):43-51. PubMed ID: 24781258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dehydroepiandrosterone and quinapril on nephropathy in obese Zucker rats.
    Richards RJ; Porter JR; Inserra F; Ferder LF; Stella I; Reisin E; Svec F
    Kidney Int; 2001 Jan; 59(1):37-43. PubMed ID: 11135055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.